Astrazeneca (AZN) Cash & Equivalents (2009 - 2026)

Astrazeneca's Cash & Equivalents history runs 18 years deep, the most recent figure standing at $7.6 billion for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 44.55% year-over-year to $7.6 billion; the TTM figure through Mar 2026 stood at $7.6 billion (up 44.55% YoY), while the FY2025 annual figure was $5.7 billion, up 4.06% from the prior year.
• Cash & Equivalents was $7.6 billion for Q1 2026 at Astrazeneca, up from $5.7 billion in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $8.1 billion in Q3 2025 to a low of $1.2 billion in Q4 2024.
• Historically, Cash & Equivalents has averaged $5.8 billion across 5 years, with a median of $5.8 billion in 2022.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 79.2% in 2024, then surged 370.04% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $6.2 billion in 2022, then slipped by 5.29% to $5.8 billion in 2023, then plunged by 79.2% to $1.2 billion in 2024, then soared by 370.04% to $5.7 billion in 2025, then surged by 32.38% to $7.6 billion in 2026.
• The last three Cash & Equivalents figures came in at $7.6 billion (Q1 2026), $5.7 billion (Q4 2025), and $8.1 billion (Q3 2025), per Business Quant data.